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The aim of our study was to assess the diagnostic usefulness of the gray level parameters to distinguish osteolytic lesions using
radiological images.Materials and Methods. A retrospective study was carried out. A total of 76 skeletal radiographs of osteolytic
metastases and 67 radiographs of multiple myeloma were used. The cases were classified into nonflat (MM1 and OL1) and flat
bones (MM2 and OL2). These radiological images were analyzed by using a computerized method. The parameters calculated
were mean, standard deviation, and coefficient of variation (MGL, SDGL, and CVGL) based on gray level histogram analysis of a
region-of-interest. Diagnostic utility was quantified bymeasurement of parameters on osteolytic metastases andmultiple myeloma,
yielding quantification of area under the receiver operating characteristic (ROC) curve (AUC). Results. Flat bone groups (MM2 and
OL2) showed significant differences in mean values of MGL (𝑃 = 0.048) and SDGL (𝑃 = 0.003). Their corresponding values of
AUC were 0.758 for MGL and 0.883 for SDGL in flat bones. In nonflat bones these gray level parameters do not show diagnostic
ability.Conclusion.The gray level parametersMGL and SDGL show a good discriminatory diagnostic ability to distinguish between
multiple myeloma and lytic metastases in flat bones.
1. Introduction
One of the most important first steps when evaluating a lytic
bone lesion is to know the age of the patient. Some of the
lytic lesions that are largely confined to certain age groups are
multiple myeloma and osteolytic metastases in the middle-
aged and elderly.
Multiple myeloma is a malignant tumour of plasma cells
that causes widespread lytic bone damage. It is the most
common primary tumour of bone and is found in the spine,
skull, ribs, sternum, and pelvis but may affect any bone with
hematopoietic red marrow. The average patient age is over
fifty years and the male-to-female ratio is 3 : 2. The diagnosis
is based on laboratory parameters in combination with bone
marrow biopsy or aspiration. The radiological appearance of
multiple myeloma is characterized by irregular lytic defects
of different sizes. These lytic areas are often described as
“punched out” and have no periosteal reaction [1]. Moreover,
it is not easy to distinguish between multiple myeloma bone
disease and lytic bone metastases on plain film. In staging,
treatment evaluation, and prognosis of patients with multiple
myeloma, detection of lytic bone lesions has critical value.
Although, new imaging techniques have been introduced
to assess the extent and severity of multiple myeloma,
most institutions still use radiograph as a complementary
technique to evaluate disease stage (progression and therapy
response) [2].
Metastatic cancer is the most common malignant sec-
ondary bone tumour. Skeletal metastases are classified
according to their radiologic appearance as osteolytic, mixed,
or osteoblastic. Cancers that are most likely to metastasize to
bone are breast, lung, prostate, thyroid, and kidney.The aver-
age patient age is over forty years. The distribution of skeletal
metastases in adults is very similar to that of hematopoietic
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red marrow, which coincides with the trabecular and flat
bones [3]. Thus, the typical radiological imaging of a lytic
metastasis appears as an area of loss of mineral bone density.
Diagnosis and classification of these bone lesions are
commonly made by a variety of imaging modalities, includ-
ing plain radiography (XR), skeletal scintigraphy (SS), com-
puted tomography (CT),magnetic resonance imaging (MRI),
and positron emission tomography (PET) [3, 4].
X-ray is the first imaging study undertaken to detect lytic
metastases and myeloma-caused bone damage to demon-
strate loss or thinning of bone (osteoporosis or osteopenia),
holes in bone (lytic lesions), and/or fractures.Despite low cost
and wide availability, X-rays have an important limitation:
30% of the bone must be missing before damage can be
revealed.
The lytic bone disease in multiple myeloma differs from
that in other cancer patients who have lytic bone metastases.
Although increased osteoclastic bone destruction is involved
inmultiplemyeloma in contrast to osteolyticmetastases, once
the multiple myeloma tumour burden exceeds 50% in a local
area, osteoclast activity is either suppressed or absent [5].
The aim of our study was to assess the diagnostic useful-
ness of the gray level parameters to distinguish between oste-
olytic metastases and multiple myeloma from radiographic
images.
2. Materials and Methods
2.1. Imaging Database. The data collection was scheduled
in two separate cycles. In the first cycle a set of 76 antero-
posterior radiographs with confirmed osteolytic metastases
(OL) as determined from 99mTc-bone scintigraphy and
18F-FDG PET examinations were included in this study.
Patients presented antecedent of adenocarcinoma of the
lung with evidence of distant metastases (M1) and no prior
treatment was studied. Their mean age was 61 years (range
43–81 years, 18 males and 27 females). In the second cycle
a total of 67 anteroposterior radiographs with confirmed
multiple myeloma (MM) as determined from 18F-FDG PET
examination and laboratory parameters were included too.
Themedian age was 63 years (range 51–72 years, 17 males and
14 females).
Radiographs were performed with the following settings:
70–80 kVp, 100 cm focus to film distance, and use of a fast
screen and film cassette (30 cm × 40 cm).
The Institutional Review Boards of the participating
center approved this retrospective study. The radiological
images used in this paper were obtained from the database of
“Medical Imaging Research” Laboratory at theDepartment of
Physiological Sciences II, Faculty of Medicine, University of
Barcelona. Patient confidentiality was protected.
2.2. Methods. In an earlier work, an image processing and
analysis method was introduced in order to characterize
skeletal digitized radiographs. Hence, by means of gray level
parameters on digitized radiographs we classified healthy
bone according to histological and anatomical features. So,
we reported an optimized healthy bone classification into two
groups: flat or nonflat bones (trabecular, cortical) [6].
The images were processed and characterizedwith a com-
puterized method developed by our group in an earlier work
[6–8]. The workflow of image processing analysis includes
the following steps: (1) image acquisition, (2) selection of a
region of interest (ROI), (3) filtering for noise reduction, (4)
gray level histogram (parameters output), and (5) statistical
analysis to distinguish between groups.
The radiographs were digitized by using a laser scanner
(KFDR-S; Konica, Tokyo, Japan) with a 0.175mm pixel size,
a matrix size of 2,048 × 2,048, and 12-bit gray-scale levels.
Digitizer performance was evaluated employing a quality
control protocol [5].
The images were processed using ImageJ software (NIH
image program). The cases were obtained from region of
interests of 40 × 50 pixels outlined manually on each
radiograph. Only one ROI from each radiograph was used.
They were classified into two groups, flat or nonflat bones,
according to histological and anatomical bone features [6].
The final set contained 67 ROIs frommultiple myeloma bone
disease (flat bone: 36; nonflat bone: 31) and 45 ROIs from
osteolytic metastases (flat bone: 41; nonflat bone: 35).
Due to the presence of intensity inhomogeneities and
noise on radiographs inherent to imaging process, the ROI
was subjected to an anisotropic diffusion filter [9, 10] which
smoothed out the noise and preserved the edge and contrast
associated with bone structure at the same time.
The parameters calculated from radiographs were based
on the gray level histogram analysis of ROI (see Figure 1):
mean gray level (MGL), standard deviation gray level
(SDGL), and coefficient of variation (CVGL). The mean gray
level is defined as the value given by the average of gray level
of each ROI pixel. MGL provides 4096 gray levels because we
use images of 12 bit grayscale (0–4096, where 0 is equivalent
to black and 4096 to white).The standard deviation gray level
of ROI pixel calculates the dispersion of gray values from
the average (MGL). SDGL can be expressed in relation to
MGL as a coefficient of variation (in %) and is expressed as
CVGL = (SDGL/MGL) ⋅ 100.
2.3. Statistical Analysis. The data were analyzed using SPSS
16.0 (SPSS, Inc., Chicago, IL). Standard descriptive summary
statistics was used to show overall trends in data. The data
comparison among bone groups was implemented using
Student’s paired 𝑡-test. Nonparametric estimation of areas
under ROC curve (AUC) was carried out to assess the diag-
nostic ability of each parameter considered (MGL, SDGL,
and CVGL) in multiple myeloma bone disease and osteolytic
metastases. Significance was considered to be reached at
𝑃 < 0.05.
3. Results
Table 1 shows the descriptive statistics for mean gray level,
standard deviation gray level, and coefficient of variation gray
level parameters for the groups: osteolyticmetastases (nonflat
bone: OL1; flat bone: OL2) and multiple myeloma (nonflat















Figure 1: Two zooms of different plain radiographs showing osteolytic regions of interest (ROI). Gray level histogram for the outlined ROI
is shown on the right side for each case. (a) Multiple myeloma (case 3, skull); (b) lytic metastasis (case 7, skull).
Table 1:Descriptive statistics for the three parameters studied:mean
(MGL), standard deviation (SDGL), and coefficient of variation
(CVGL) of gray level.
Groups Mean St. dev. Min. Max.
MGL
MM1 1710.42 332.25 1264 2017
OL1 1634.13 269.36 1312 2000
MM2 1593.21 140.87 1406 1840
OL2 1744.53 176.75 1472 2096
SDGL
MM1 256.89 12.98 242.37 277.56
OL1 258.56 20.43 228.64 295.52
MM2 248.12 9.51 238.10 264.27
OL2 270.66 16.80 240.64 301.28
CVGL
MM1 15.02 3.09 12.64 20.43
OL1 16.14 2.41 12.85 20.34
MM2 15.57 1.45 13.23 16.87
OL2 15.64 1.56 12.02 18.61
Note. Multiple myeloma: MM1 (nonflat bone) and MM2 (flat bone); oste-
olytic metastases: OL1 (nonflat bone) and OL2 (flat bone).
bone:MM1; flat bone:MM2).When comparing the gray level
parameters between nonflat bone groups (MM1 and OL1)
there were no significant differences. In contrast, flat bone
groups (MM2 and OL2) showed significant differences in
mean values of MGL (𝑃 = 0.048) and SDGL (𝑃 = 0.003).
Table 2: AUC values of the ROC curve for the three parameters
(mean (MGL), standard deviation (SDGL), and coefficient of vari-
ation (CVGL) of gray level) considered and their corresponding
significance. Null hypothesis tested (AUC = 0.5) corresponds to a
null diagnostic value to differentiate betweenmultiple myeloma and
osteolytic metastases groups.
AUC values
Groups MGL SDGL CVGL










Note. Multiple myeloma: MM1 (nonflat bone) and MM2 (flat bone); oste-
olytic metastases: OL1 (nonflat bone) and OL2 (flat bone). AUC: the area
under the ROC curve.
Table 2 shows the AUC values for the groups studied.
There were significant values of AUC when comparing flat
bone groups of multiple myeloma and osteolytic metastases
(MM2 and OL2) for the MGL and SDGL parameters (AUC
values: MGL = 0.758; SDGL = 0.883). These results are
illustrated in Figure 2: AUC values correspond to the ROC
curve when comparing gray level parameters for flat bone
groups. Nevertheless, when comparing nonflat bone groups


















Figure 2: ROC curve for the three parameters considered (mean
(MGL), standard deviation (SDGL), and coefficient of variation of
gray level (CVGL)) when comparing flat bone groups (multiple
myeloma MM2 versus osteolytic metastases OL2).
(MM1 and OL1) there were no significant values of AUC for
gray level parameters.
4. Discussion
This study seeks to evaluate the diagnostic accuracy of gray
level parameters to distinguish osteolytic lesions from two
different pathologies (metastases and multiple myeloma)
using radiographs.
As for nonflat bones, gray level parameters were not
able to distinguish between multiple myeloma and osteolytic
metastases groups.
As regards flat bones, multiple myeloma had gray levels
lower than those of lytic metastases for MGL and SDGL
parameters (𝑃 = 0.048 and 𝑃 = 0.003, resp.). In contrast,
the CVGL parameter was not able to distinguish between
these groups (𝑃 = 0.89). When comparingmultiple myeloma
and osteolytic metastases, SDGL proved to have the best
discriminatory ability (AUC = 0.883) and MGL a good
discriminatory ability (AUC = 0.758). This is important
for establishing the differential diagnosis in the two groups
because the distribution of skeletal metastases and multiple
myeloma bone disease is closely related to the location of the
flat bones (e.g., skull, ribs, sternum, and pelvis).Histologically
flat bone is made up of the two cortical thin sheets, involving
a small proportion of trabecular tissue (diploe: soft spongy
material containing bonemarrow).The finding thatmyeloma
lesions in flat bones appear to manifest lower gray level
values might be explained as follows: in multiple myeloma,
osteoclasts accumulate only at bone resorbing surfaces adja-
cent to myeloma cells; their levels are not increased in areas
uninvolved with tumor. In addition to the increase in bone
resorption, bone formation is suppressed so that bone lesions
in patients with myeloma become purely lytic (there is no
osteoblastic response). In osteolytic metastases, the mecha-
nisms responsible for tumor growth in bone are complex and
involve tumor stimulation of the osteoclast and the osteoblast
as well as the response of the bone microenvironment [11].
There are currently different imaging modalities (plain
radiography, skeletal scintigraphy, computed tomography,
magnetic resonance imaging, and positron emission tomog-
raphy) to diagnose multiple myeloma bone disease or lytic
metastases. An accurate assessment of the response of both
pathologies to treatment requires the structural changes
in the bone to be visualized. In this regard, each of the
aforementioned imaging techniques has its pros and cons
[12–15].Nowadays, the baseline diagnosis evaluation to detect
lytic bone lesions comprises conventional radiography too [6,
9, 10, 15]. Early identification of direct anatomic visualization
of the bone or tumor could lead to changes in patient
management and quality of life. Although bone metastases
can be treated, their response to treatment is considered
“unmeasurable,” which excludes patients with cancer and
bone metastatic disease from participating in clinical trials
of new treatments [14]. Radiography is commonly used to
evaluate symptomatic sites and is a useful complement to
scintigraphy for clarifying nonspecific or atypical findings or
for following up cases in which clinical findings indicate bone
pain but where scintigraphy findings are negative.
The accurate detection of lytic bone lesions should
improve by quantifying these lesions, thereby paving the way
for computerized methods that would enable us to quantify
the selected regions in order to reduce subjectivity in the
interpretation of the image, calculate the ideal parameters,
define patterns of normality, and determine the pathology by
evaluating deviations of these indexes. Moreover, this digital
method can be useful to study the evolution of these lytic
bone lesions under treatment, to recognize new lesions, and
to differentiate it from previous lesions.
The advantages of thismethodology are its wide diffusion,
low cost, and improved patient comfort.
This methodology could be applied to questions of clini-
cal relevance. For example, bisphosphonates are administered
as a preventive treatment of bone complications encountered
in multiple myeloma and osteolytic metastases. However, in
recent years a relationship has been established between these
drugs and a new bone injury: jaw osteonecrosis [11]. This
lesion is characterized by avascular necrosis of bone that was
isolated from the jaws.Thismethodology offers the possibility
of studying radiological manifestations of this disease.
This study determined preliminary results about the
role of gray level image parameters on digitized radiograph
in quantifying and differentiating the two bone diseases.
Consequently, our results demonstrate that gray level param-
eters quantify multiple myeloma and lytic metastases bone
lesions in flat bones accurately. This can be helpful as a
complementarymethod for differential diagnosis. Most cases
(80–90% approximately) of bone metastases and multiple
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myeloma bone lesions are located in the axial skeleton (spine,
ribs, skull, femur, and pelvis), which are mainly flat bones.
In conclusion, the gray level parameters MGL and SDGL
show a good discriminatory diagnostic ability to distinguish
between multiple myeloma and lytic metastases in flat bones
(AUC = 0.758 and 0.883, resp.).
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